BRAF and neoplasm: Patients with tumours expressing these oncoproteins will not benefit from targeted therapy directed against BRAF, in particular if paradoxically acting type I1/2 compounds like dabrafenib are involved and the mutational status of RAS proteins or their activators or negative regulators such as NF1 is unknown.